| Name | Title | Contact Details |
|---|
TriLink BioTechnologies, part of Maravai LifeSciences, is a prominent contract development and manufacturing organization (CDMO) based in San Diego. Founded in 1996, the company specializes in the synthesis of nucleic acids, nucleoside triphosphates (NTPs), and mRNA capping analogs. TriLink provides advanced scale-up expertise and unique production capabilities for mRNA, oligonucleotides, and plasmids, catering to clients in therapeutics, vaccines, diagnostics, and biopharmaceutical innovations. The company offers custom synthesis and manufacturing services, supporting clients from early research through clinical trials. TriLinks proprietary CleanCap® technology enhances mRNA manufacturing efficiency, resulting in improved yields. Their product portfolio includes custom and modified oligonucleotides, plasmids, mRNA, and CleanCap® reagents. TriLink adheres to stringent quality systems compliant with ICH Q7, GMP guidelines, and ISO 9001:2015 standards, ensuring high-quality manufacturing for a diverse range of applications. The company collaborates with various organizations, including the U.S. Department of Defense, to support the development of critical mRNA vaccines and therapeutics.
The leading Layer 2 for NFTs that’s fully secured by Ethereum. Scale your game in hours.
Thud Interactive is a Bel Air, MD-based company in the Business Services sector.
The Drexel Heights Fire District will deliver on its promise to the community through the following core organizational values and beliefs. Our values include integrity, commitment, professionalism and dedication.
Biocartis is a molecular diagnostics company based in Mechelen, Belgium, founded in 2007. The company focuses on enhancing molecular testing through its proprietary Idylla TM Platform, which aims to make personalized medicine accessible by providing fast and convenient testing solutions suitable for various laboratory settings. Biocartis specializes in oncology diagnostics, offering a range of tests for cancers such as melanoma, colorectal, lung, brain, blood, and breast cancer. The Idylla Platform is a fully automated system that utilizes real-time PCR technology, enabling rapid in-house testing with results available in 30 to 150 minutes. In addition to oncology, Biocartis develops tests for infectious diseases, including panels for SARS-CoV-2, flu, and RSV, as well as the SeptiCyte RAPID test for host response. The company collaborates with major pharmaceutical and biotechnology firms, including Amgen and Bristol-Myers Squibb, to advance its testing capabilities and expand its diagnostic applications. Biocartis is committed to developing four to five new diagnostic applications each year, further enhancing its impact in the molecular diagnostics field.